ATE334694T1 - Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln - Google Patents

Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln

Info

Publication number
ATE334694T1
ATE334694T1 AT02800641T AT02800641T ATE334694T1 AT E334694 T1 ATE334694 T1 AT E334694T1 AT 02800641 T AT02800641 T AT 02800641T AT 02800641 T AT02800641 T AT 02800641T AT E334694 T1 ATE334694 T1 AT E334694T1
Authority
AT
Austria
Prior art keywords
thymulin
peptides
producing pain
pain relieves
relieves
Prior art date
Application number
AT02800641T
Other languages
English (en)
Inventor
Mireille Dardenne
Jean-Marie Pleau
Jean-Francois Bach
Nayef Saade
Bared Safieh-Garabedian
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE334694T1 publication Critical patent/ATE334694T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02800641T 2001-10-09 2002-10-08 Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln ATE334694T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0112984A FR2830451B1 (fr) 2001-10-09 2001-10-09 Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur

Publications (1)

Publication Number Publication Date
ATE334694T1 true ATE334694T1 (de) 2006-08-15

Family

ID=8868083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02800641T ATE334694T1 (de) 2001-10-09 2002-10-08 Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln

Country Status (11)

Country Link
US (1) US7309690B2 (de)
EP (1) EP1450843B1 (de)
JP (1) JP4277684B2 (de)
AT (1) ATE334694T1 (de)
AU (1) AU2002362710B2 (de)
CA (1) CA2463549C (de)
DE (1) DE60213648T2 (de)
ES (1) ES2272811T3 (de)
FR (1) FR2830451B1 (de)
IL (2) IL161319A0 (de)
WO (1) WO2003030927A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192300A1 (en) 2003-01-28 2013-08-30 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN102772783A (zh) * 2007-01-25 2012-11-14 中国生化制药工业协会 血清胸腺因子在制备抗肿瘤药物、肿瘤物理及化学治疗药物的保护药物方面的用途
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
FR2930156B1 (fr) * 2008-04-21 2011-10-28 Cll Pharma Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010065751A2 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2010078449A2 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9468662B2 (en) 2010-07-12 2016-10-18 Orphit Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN104902930A (zh) 2012-08-21 2015-09-09 阿德利克斯公司 在治疗与液体潴留或盐分过载相关的疾病和胃肠道疾病中用于抑制nhe-介导的反向转运的化合物和方法
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
HUE044550T2 (hu) 2013-04-12 2019-11-28 Ardelyx Inc NHE-3 megkötõ vegyületek és foszfát transzport gátlási módszerek
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
CN109219444A (zh) * 2016-06-06 2019-01-15 临床干细胞有限公司 用于毛发生长的肽
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156766B (it) * 1977-05-25 1987-02-04 Anvar Polipeptidi dotati di attivita' timica o antagonista e procedimento per la loro sintesi
GR75636B (de) 1980-05-22 1984-08-02 Inst Nat Sante Rech Med
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5288706A (en) * 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others
JPH06192120A (ja) * 1992-12-24 1994-07-12 Mitsui Toatsu Chem Inc 腎臓の組織・細胞の損傷・破壊の予防・治療剤
JP3751986B2 (ja) * 1994-06-21 2006-03-08 英良 横沢 医薬組成物
US5639726A (en) * 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
US5808009A (en) * 1996-09-23 1998-09-15 North Dakota State University Research Foundation Method of affinity purifying antibodies

Also Published As

Publication number Publication date
US7309690B2 (en) 2007-12-18
ES2272811T3 (es) 2007-05-01
CA2463549A1 (fr) 2003-04-17
EP1450843A2 (de) 2004-09-01
AU2002362710B8 (en) 2003-04-22
AU2002362710B2 (en) 2007-06-28
FR2830451B1 (fr) 2004-04-30
IL161319A0 (en) 2004-09-27
DE60213648D1 (de) 2006-09-14
JP4277684B2 (ja) 2009-06-10
WO2003030927A3 (fr) 2003-10-09
FR2830451A1 (fr) 2003-04-11
CA2463549C (fr) 2011-12-20
WO2003030927A2 (fr) 2003-04-17
EP1450843B1 (de) 2006-08-02
JP2005515972A (ja) 2005-06-02
IL161319A (en) 2008-11-26
US20050261194A1 (en) 2005-11-24
DE60213648T2 (de) 2007-08-02

Similar Documents

Publication Publication Date Title
ATE334694T1 (de) Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln
IL161591A0 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DE60225118D1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
DE60138549D1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
ATE232393T1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung
NL300830I1 (nl) Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
GB2367061A (en) Peptides
FI20050753A (fi) Uudet peptidit
HUP9900789A2 (hu) Lefelé irányuló szabályozásra rezisztens C3 konvertáz
DE69837265D1 (de) Polypeptide zur regenerierung des nervensystems
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
DE602006017806D1 (de) Behandlung von neurodegeneration
EP1303291A4 (de) Anti-hiv und anti-tumor lysozympeptide sowie fragmente
HUP0102046A2 (hu) CD137 alkalmazása perifériás monociták proliferációjának serkentésére
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
ATE237345T1 (de) Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten
SE9703287D0 (sv) Peptides
DE60329838D1 (de) Verwendung von alpha-s2 casein vorläufer-abgeleiteten peptiden
ATE374021T1 (de) Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post- chirurgischen schmerzbehandlung
DE50000676D1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis
PL326631A1 (en) Compounds exhibiting haemoregulatory activity
DE69832075D1 (de) Verwendung von eprosartan zur behandlung von isoliertem systolischem bluthochdrucks

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties